Medical Abortion Clinical Trial
Official title:
De-Medicalizing Mifepristone Medical Abortion
This study will investigate the possibility that medical abortion using mifepristone and
misoprostol - a safe, proven therapy for terminating early first trimester pregnancy - can
be administered in a manner that is simpler and less costly than that routinely employed in
the United States.
The researchers hypothesize that:
1. Practitioners themselves, based on history and examination but without sonography, are
able to dependably and correctly determine which patients are eligible for medical
abortion and which patients either are not eligible or require further evaluation to
determine eligibility.
2. Practitioners themselves, based on a symptom diary and low-sensitivity pregnancy test
but without sonography, are able to dependably and correctly determine when a
successful medical abortion has taken place and when referral for other possible
outcomes should be made.
3. A symptom diary and low-sensitivity pregnancy test are safe and effective means of
separating those women who could benefit from a follow-up visit from those who do not
need one.
Mifepristone medical abortion has been available in France for a decade and a half and in
the United States since 2001. Over this time, it has been demonstrated to be as safe as or
safer than either surgical abortion or carrying a pregnancy to term. Furthermore, as medical
abortion employs medications rather than surgery to terminate a pregnancy, it has the
potential to greatly increase the availability of locations providing abortion services in
the US, eliminating as it does the need for expensive equipment and surgical training.
Unfortunately, however, although the availability of medical abortion in the US has
increased with time, it has yet to achieve its full potential. In large part this appears to
be due to two factors which inhibit providers from offering, and women from choosing, the
procedure: 1) Although the approved US medical abortion regimen does not require providers
to use ultrasound examination as part of the procedure, it has become common practice for
providers to do so. This both increases the cost of the procedure and limits the number of
facilities that can offer it. 2) While surgical abortion typically requires only one clinic
visit, medical abortion requires (officially) three or (in practice) two visits, making it
more expensive, less convenient, and less attractive to women.
There is already a great deal of evidence that medical abortion can be safely offered with
two (or even fewer) office visits, and without routine ultrasonography. Most medical
abortions in the United States, in fact, currently require only two visits, and the
possibility exists that women could self-screen at home, based on a symptom checklist, to
determine if the second of these (the follow-up visit) is necessary – an approach that could
spare the large majority of medical abortion clients who have uncomplicated courses an extra
trip to the clinic. There are, in addition, several less-expensive and less
technology-intensive approaches to gathering the diagnostic information currently being
provided, pre- and post-procedure, by ultrasonography.
The purpose of the current study is to test the feasibility and efficacy of an approach to
medical abortion that forgoes the routine use of ultrasonography. It will also provide
evidence on the feasibility of eliminating the requirement for a universal follow-up visit
based on self-screening by medical abortion clients. In providing data to make these tests,
however, the study protocol will not in any way abridge the medical abortion care currently
received by clients at the participating facilities. The study will permit clients to
receive standard care (including a follow-up visit and pre- and post-procedure ultrasound
examinations in all cases) while gathering valuable information which, we hope, will provide
a basis for simplifying standard care in the future.
The research questions to be answered by the study are:
1. Do an interview with the abortion client, a pregnancy test and a physical exam provide
adequate information to determine which abortion clients are eligible for the medical
abortion procedure and which should be referred for sonography (or other diagnostic
tests) before making such a determination?
2. Can a self-administered symptom diary and a follow-up low-sensitivity pregnancy test
provide an adequate basis to determine whether a woman has undergone a successful
medical abortion or whether she requires a sonographic exam (or other diagnostic test)
in order to make this determination?
3. Does a post-abortion pelvic examination provide valuable additional information for
determining whether a woman has undergone a successful medical abortion or whether she
requires a sonographic exam (or other diagnostic test) in order to make this
determination?
4. Can a self-administered symptom diary and a low-sensitivity pregnancy test provide an
adequate basis for determining which medical abortion clients require a follow-up
visit?
The research hypotheses are:
1. Practitioners themselves, based on history and examination but without sonography, are
able to dependably and correctly determine which patients are eligible for medical
abortion and which patients either are not eligible or require further evaluation to
determine eligibility.
2. Practitioners themselves, based on a symptom diary and low-sensitivity pregnancy test
but without sonography, are able to dependably and correctly determine when a
successful medical abortion has taken place and when referral for other possible
outcomes should be made.
3. A symptom diary and low-sensitivity pregnancy test are safe and effective means of
separating those women who could benefit from a follow-up visit from those who do not
need one.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02745093 -
Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks
|
Phase 4 | |
Completed |
NCT02570204 -
Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests
|
N/A | |
Completed |
NCT01487213 -
Routine Follow-up Versus Self-assessment in Medical Abortion
|
N/A | |
Terminated |
NCT05119439 -
Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
|
Phase 4 | |
Terminated |
NCT04941443 -
Methadone and Medication Abortion
|
Phase 4 | |
Completed |
NCT02985229 -
Acceptability and Feasibility of Medical Abortion in Singapore
|
Phase 3 | |
Completed |
NCT01920022 -
Quickstart of Nexplanon® at Medical Abortion
|
Phase 4 | |
Completed |
NCT00472394 -
Determining Women's Preferences for Medical Abortion Using Willingness to Pay
|
N/A | |
Completed |
NCT03604341 -
Cannabinoids for Pain Control During Medical Abortion
|
Phase 4 | |
Completed |
NCT00907725 -
Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?
|
N/A | |
Completed |
NCT03148587 -
Medical Abortion Self-Confirmation (MASC)
|
N/A | |
Completed |
NCT00621543 -
Insertion of an Intrauterine Device (IUD) After Medical Abortion
|
N/A | |
Completed |
NCT02343913 -
Simplifying Menstrual Regulation (MR): Post Abortion Care in Pakistan
|
N/A | |
Completed |
NCT01856777 -
Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy
|
N/A | |
Recruiting |
NCT00920465 -
Treatment Regimens for Mifegyne and Cytotec
|
Phase 3 | |
Completed |
NCT05532085 -
Assessment of Pain During an Abortion With Knowledge of the Predictive Factors of Pain.
|
||
Completed |
NCT00997347 -
The Extended Gestational Age Medical Abortion Study
|
Phase 4 | |
Completed |
NCT03014193 -
Simplifying First Trimester Medical Abortion Follow-up
|
N/A | |
Recruiting |
NCT04905251 -
Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion
|
||
Completed |
NCT04181541 -
Midlevel Versus Physician-provided Medical Abortion in the Second Trimester
|
N/A |